Relugolix

CAS : 737789-87-6

Ref. 3D-MEB78987

Informations sur le produit

• Nom: Relugolix
• Synonymes: 1-[4-[1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea, N-[4-[1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N′-methoxyurea, Orgovyx, Rvt 601, TAK-385,Relugolix, Tak-385, Urea, N-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N′-methoxy-

Description

Relugolix is a hormone antagonist that blocks the effects of androgens such as testosterone. It is used to treat prostate cancer, endometriosis, and other conditions. Relugolix has been shown to be an effective treatment for prostate cancer when used in combination with other therapies such as platinum-based chemotherapy or radiation therapy. Relugolix has been shown to block not only the effects of testosterone but also other hormones like estrogens and progesterone, which may be beneficial in treating endometriosis. Relugolix has also been shown to inhibit urothelial carcinoma cells.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 623.63 g/mol
• Formule: C₂₉H₂₇F₂N₇O₅S
• Degré de pureté: Min. 95%